Can elevated DHT persist despite below-optimal total and free testosterone?

High circulating DHT despite low total and free testosterone is physiologically unusual in a 52-year-old man, but the proposed combination has a credible mechanistic basis. It should not be assumed from a single laboratory pattern or nonspecific liver-test abnormalities.

Mechanistic basis

• DHT is usually produced by peripheral 5α-reduction of testosterone. Greater local 5α-reductase activity could therefore preserve DHT relative to testosterone.
• Human prostate tissue also supports an alternative route: androstenedione → 5α-androstanedione → DHT. This bypasses testosterone and means low measured testosterone does not absolutely rule out DHT synthesis.
• The liver materially contributes to DHT elimination through 3α-hydroxysteroid dehydrogenase–mediated reduction and UGT-mediated glucuronidation, followed by renal and biliary excretion. Reduced elimination could theoretically contribute to higher DHT when coupled with increased production.

Limits of the proposed explanation

• No direct adult-male evidence establishes a combined phenotype of high adrenal precursor supply, increased 5α-reduction, impaired hepatic clearance, and elevated circulating DHT with confirmed low total and free testosterone.
• The testosterone-bypassing androstenedione pathway is demonstrated particularly in prostate tissue; its quantitative contribution to serum DHT in typical adult men is unknown.
• Available liver-disease observations do not support a simple “impaired clearance causes high DHT” model: in cirrhosis, both testosterone and DHT were lower, and hepatocellular-carcinoma data associated higher bilirubin/GGT with lower DHT.
• Progesterone should not be considered a direct adrenal precursor of DHT, and the available evidence does not link DHEA-S specifically to this pattern.

Clinical implications

• Serum DHT is ordinarily approximately one-tenth of total testosterone and is assay- and tissue-metabolism-dependent. Confirm an unexpected result with repeat morning testing using validated LC–MS/MS.
• Interpret alongside SHBG, gonadotropins, liver-disease severity, medications, supplements, and any androgen exposure.

Bottom line

• The claim is biologically plausible but remains a low-confidence explanation for an uncommon laboratory pattern; objective confirmation and broader endocrine and hepatic context are essential before attributing elevated DHT to precursor supply, enhanced conversion, or reduced clearance.